Mirae Asset Global Investments Co. Ltd. Increases Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Mirae Asset Global Investments Co. Ltd. increased its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.8% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 23,809 shares of the specialty pharmaceutical company’s stock after purchasing an additional 872 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Supernus Pharmaceuticals were worth $689,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of SUPN. China Universal Asset Management Co. Ltd. raised its stake in Supernus Pharmaceuticals by 96.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,401 shares of the specialty pharmaceutical company’s stock worth $39,000 after buying an additional 687 shares in the last quarter. Covestor Ltd raised its stake in Supernus Pharmaceuticals by 115.0% in the third quarter. Covestor Ltd now owns 2,350 shares of the specialty pharmaceutical company’s stock worth $65,000 after buying an additional 1,257 shares in the last quarter. Envestnet Portfolio Solutions Inc. bought a new position in Supernus Pharmaceuticals in the third quarter worth approximately $262,000. Profund Advisors LLC raised its stake in Supernus Pharmaceuticals by 17.7% in the third quarter. Profund Advisors LLC now owns 9,660 shares of the specialty pharmaceutical company’s stock worth $266,000 after buying an additional 1,454 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Supernus Pharmaceuticals by 28.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,949 shares of the specialty pharmaceutical company’s stock worth $274,000 after buying an additional 2,203 shares in the last quarter.

Supernus Pharmaceuticals Stock Up 1.0 %

Shares of SUPN stock opened at $30.26 on Thursday. The business’s fifty day simple moving average is $31.47 and its 200-day simple moving average is $28.59. Supernus Pharmaceuticals, Inc. has a 12-month low of $21.99 and a 12-month high of $38.09.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.39). The business had revenue of $164.30 million for the quarter, compared to analyst estimates of $155.03 million. Supernus Pharmaceuticals had a return on equity of 0.14% and a net margin of 0.22%. The business’s revenue for the quarter was down 1.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.43 earnings per share. As a group, research analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.16 earnings per share for the current year.

Insider Transactions at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 5,000 shares of the company’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $30.21, for a total transaction of $151,050.00. Following the transaction, the vice president now directly owns 8,570 shares of the company’s stock, valued at $258,899.70. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, VP Padmanabh P. Bhatt sold 12,364 shares of the company’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $35.31, for a total value of $436,572.84. Following the transaction, the vice president now directly owns 8,570 shares of the company’s stock, valued at approximately $302,606.70. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 5,000 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $30.21, for a total value of $151,050.00. Following the completion of the transaction, the vice president now directly owns 8,570 shares in the company, valued at $258,899.70. The disclosure for this sale can be found here. Over the last three months, insiders have sold 35,739 shares of company stock valued at $1,227,433. Corporate insiders own 8.76% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Piper Sandler reduced their price objective on shares of Supernus Pharmaceuticals from $45.00 to $41.00 and set an “overweight” rating for the company in a research note on Wednesday, February 28th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.